Doctors at Memorial Sloan-Kettering Cancer Center recently declared they would not use Zaltrap (Sanofi), for advanced colorectal cancer. In a New York Times editorial, they suggested the extraordinary cost for incremental benefit could not justify its use. Sanofi appeared to cave to the pressure and announced a 50% discount - which only made things worse. This August, Zaltrap received FDA approval for the treatment of advanced colorectal cancer. In ...

Read more...

1 Pages